AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00315354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: Feeding protocol, all foods prepared in a metabolic kitchen
Study NCT00677456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: P-I reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
Study NCT01489020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous immunotherapy with DPT extract
Description: Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
Study NCT01489020 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous depot placebo
Description: Increasing doses of subcutaneous depot placebo in three different scales
Study NCT02158650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Based Informed Consent
Study NCT00777803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))
Description: NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
Study NCT00777803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (Vistabel®)
Description: OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
Study NCT02873286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV
Description: MVA-mBN294B
Study NCT02873286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline, sterile
Study NCT04535739 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation
Description: 25Gy/2.5Gy/10f were given for PCI patients
Study NCT04535739 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: prophylactic cranial irradiation
Description: 25Gy/2.5Gy/10f were given for PCI patients
Study NCT03257488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: type IV portable monitoring (Somnocheck micro Weinmann)
Description: Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
Study NCT02930122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra (150mg)
Description: intraarticular administration
Study NCT02930122 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline intraarticularly
Description: intraarticular administration
Study NCT01958177 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
Description: Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
Study NCT01277237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omacor
Description: Active comparator: omacor 4g/day
Study NCT01277237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose tablet
Description: placebo: lactose tablet 4g/day
Study NCT00824174 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 1 questionnaire, about 15-20 minutes.
Study NCT00315354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Feeding protocol, all foods prepared in a metabolic kitchen
Study NCT01853254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
Study NCT01853254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
Study NCT03494374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UCBL orthosis
Description: toe walking exercise
Study NCT04294979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The rehabilitation program will consist of both passive and active therapeutic exercises specifically aimed at restoring or maintaining muscular flexibility, range of motion, balance, coordination of movements, postural passages and transfers, and ambulation. . Furthermore, advanced robotic therapy such as Lokomat® exoskeleton (Hocoma AG, Volketswil, Switzerland), Biodex® Stability System (BSS, Biodex, Inc, Shirley, NY), G-EO System™ (Reha Technology AG, Olten, Svizzera) and Indego® Therapy (Parker USA), will be used to personalize rehabilitation treatment.
Study NCT00373295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
Study NCT00315354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very low carbohydrate diet
Description: Feeding protocol, all foods prepared in a metabolic kitchen
Study NCT03418571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171 1.5 mg/kg
Description: ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
Study NCT00373295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
Study NCT00373295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01282450 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT02861560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dHACM
Description: Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
Study NCT03635138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal nanoparticles ( O Zn and Cu)
Description: Np of OZn nanoparticles mixed with dental adhesive
Study NCT03635138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental Adhesive pure
Description: Dental Adhesive with commercial preparation
Study NCT01004419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
Study NCT01004419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faslodex (Fulvestrant)
Description: Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
Study NCT02156362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: follow up visit
Description: At least 1 follow up visit per year will be done and an additional visit if needed.
Study NCT03437434 — intervention group
Intervention type: OTHER
Intervention: Visual Acuity
Description: Ocular Examination
Study NCT03418571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered via a single inhalation once daily for 3 consecutive days.
Study NCT02832583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenkit BCT-HA Cellular Matrix
Description: To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
Study NCT01835431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administered s.c. with the remaining meals. Dose individually adjusted.
Study NCT00882700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg Capsule (Sandoz, Austria)
Study NCT00882700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R208
Description: DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
Study NCT01835431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study NCT02342314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3143753 (Part A)
Description: Administered via SC injection
Study NCT02342314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3185643 (Part B)
Description: Administered via SC injection
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP-R208 Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study NCT01835431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered s.c. at meal-times. Dose individually adjusted.
Study NCT03673722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foods consistent with a MDP
Description: We aim to increase MDP by 3 points, according to a 14-point MEDAS score
Study NCT05554900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preventive regenerative peripheral nerve interface reconstruction
Description: Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
Study NCT01772225 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Medical record abstraction form and patient survey questionnaire.
Study NCT02177669 — intervention group
Intervention type: OTHER
Intervention: quick Contrast Sensitivity Function test
Study NCT03153397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutraflora scFOS
Description: prebiotic fiber (Nutraflora scFOS via Vital AF)
Study NCT03153397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osmolite
Description: non-prebiotic fiber containing formula (Osmolite)
Study NCT02590679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venues-P Valve
Description: a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
Study NCT03955848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alloreactive NK cell infusion
Description: Alloreactive NK cell infusion
Study NCT03453060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 1
Description: Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
Study NCT03453060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 2
Description: Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
Study NCT03453060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 3
Description: Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
Study NCT03453060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-WE Thrombin- Dose 4
Description: Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
Study NCT03453060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received a single intravenous dose of placebo.
Study NCT00916604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Three increasing dose-steps with oral suspension, 8 days treatment
Study NCT00916604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension, 8 days treatment
Study NCT03378401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octenidinedihydrochlorid
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study NCT03378401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan32mg Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan32mg Placebo
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg Placebo
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Study NCT02770261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg Placebo
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Study NCT03719768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
Study NCT03719768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy
Description: Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
Study NCT00926068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HO/03/03 10µg
Study NCT00926068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01272284 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Altis® Single Incision Sling System (SIS)
Description: The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
Study NCT01450111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 50 mg, tablet, once in the morning on Day 1
Study NCT01450111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
Study NCT02342314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A and Part B)
Description: Administered via SC injection
Study NCT02342314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rGlucagon (Part B)
Description: Administered via SC injection
Study NCT00252161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with more than D2 dissection
Description: Gastrectomy with more than D2 dissection
Study NCT00252161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Description: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Study NCT01492517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ozone exposure
Description: Exposure to 0.3ppm ozone for 2 hours
Study NCT03673722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: We aim to increase PA to 150 minutes moderate activity per week.
Study NCT03673722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will be given generic healthy eating advice based
Study NCT02725619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Study NCT02725619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PST
Study NCT02822716 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: IRE treatment
Description: The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
Study NCT01492517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diesel exhaust
Description: Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
Study NCT01492517 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ozone18
Description: Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
Study NCT02822716 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study NCT03161236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercise program
Description: Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
Study NCT01492517 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
Study NCT03161236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non exercise program
Description: continue usual lifestyle
Study NCT00139594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: licarbazepine
Study NCT02754219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: DPP4-inhibitor, Evogliptin
Study NCT00620802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGT-2168
Description: (CGT-2168, one capsule each daily)
Study NCT00620802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix
Description: (clopidogrel, 75 mg)
Study NCT00544687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-191
Description: topical (mometasone furoate + nortriptyline HCl)
Study NCT00544687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: topical mometasone furoate
Study NCT00544687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline HCl
Description: topical nortriptyline HCl
Study NCT00544687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Karison® Creme
Description: topical Karison® Creme (clobetasol-17-propinate 0.05%)
Study NCT01450111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
Study NCT01450111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
Study NCT01450111 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9